News

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Novo Nordisk's total addressable market for GLP-1 drugs could grow significantly if this happens. The official WHO report that will include those recommendations is due out in August. The stock is ...
Novo Nordisk's total addressable market for GLP-1 drugs could grow significantly if this happens. The official WHO report that will include those recommendations is due out in August. Novo Nordisk ...
CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...
May 16 - As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its ...
Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price amid intensifying competition in the obesity drug market. "The changes are ...
COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...
Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...
Novo Nordisk announced Friday that Lars Fruergaard Jorgensen is stepping down by “mutual agreement” with the board—corporate speak for “things aren’t going well and someone has to take ...
Copenhagen (AFP) – Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake ...